AI-CVD vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung AI

VX1

by Volta Medical

AI Verdict

Tool A, AI-CVD, is designed for opportunistic screening of cardiovascular and multisystem diseases using existing CT scans, focusing on early detection and risk assessment. In contrast, Tool B, VX1, assists cardiac electrophysiologists in real-time during ablation procedures for atrial fibrillation and atrial tachycardia by identifying dispersed electrograms. While both are cardiology AI tools, their distinct applications—diagnostic imaging analysis versus real-time procedural guidance—make them largely complementary rather than directly comparable.

Choose AI-CVD if…

Choose AI-CVD if your primary goal is to leverage existing CT scan data for opportunistic screening and early detection of cardiovascular and multisystem diseases. This platform is ideal for identifying hidden health risks, such as coronary artery calcium or cardiac chamber abnormalities, without requiring additional imaging, radiation, or disrupting current clinical workflows.

View AI-CVD →

Choose VX1 if…

Choose VX1 if you are an electrophysiologist seeking real-time AI guidance during atrial fibrillation and atrial tachycardia ablation procedures. This software is specifically designed to assist in identifying dispersed electrograms during live interventions, aiming to reduce inter-operator variability and standardize procedural outcomes.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	VX1
Pricing	Unknown	Contact for pricing
Deployment	Unknown	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-CVD

AI-CVD integrates seamlessly into existing radiology workflows by performing opportunistic screening using already acquired CT scans, requiring no additional imaging or workflow disruption. This passive integration minimizes the burden on clinical staff. While VX1 offers a simple user interface and compatibility with existing EP systems for real-time assistance, it still requires active engagement during a complex interventional procedure.

Clinical Value

VX1

Both tools are FDA-cleared and offer significant clinical value. AI-CVD provides broad, early detection and risk stratification for cardiovascular and multisystem diseases from existing CT scans. However, VX1 directly addresses a critical need in atrial fibrillation ablation by providing real-time AI guidance to identify dispersed electrograms, which has been shown to standardize outcomes and achieve high rates of freedom from AF/AT in clinical trials.

Pricing & Value

Tie

Both AI-CVD and VX1 state 'contact for pricing,' and no public information regarding their specific pricing models, cost-effectiveness studies, or reimbursement pathways was found. Without transparent pricing or comparative value analyses, it is not possible to determine a winner in this dimension.

Enterprise Readiness

AI-CVD

AI-CVD's cloud deployment model inherently offers scalability and easier management for enterprise environments. Furthermore, HeartLung Corporation's privacy policy explicitly details HIPAA-compliant security practices, including encrypted data transmission and secure cloud infrastructure, and states they 'may operate as a HIPAA Business Associate.' VX1's integration with existing EP systems is beneficial, but its enterprise readiness regarding explicit BAA and HIPAA compliance statements is less detailed in the available information.

Innovation

VX1

While AI-CVD is innovative in leveraging existing CT scans for opportunistic screening, VX1 represents a more significant leap in real-time interventional cardiology. It is the 'first FDA cleared AI-based tool in interventional cardiac electrophysiology', providing active AI guidance during complex, high-stakes ablation procedures to standardize outcomes and reduce operator variability.

Support & Docs

VX1

VX1 explicitly mentions the availability of a 'User Manual' and 'Brochure' on its product page, indicating readily accessible documentation for users. While HeartLung's privacy policy mentions 'customer support systems', no specific details about publicly available documentation or support resources for AI-CVD were found.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	VX1
Tool Name	AI-CVD	VX1
Company	HeartLung Corporation	Volta Medical
Primary Use Case	Opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.	Assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
Target Specialties	Cardiology, Pulmonology, Radiology	Cardiology
Key AI Functionality	Automated CT-derived anatomical and density-based measurements for opportunistic screening, including Coronary Artery Calcium (CAC) scoring, valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta/pulmonary artery sizing.	AI-guided real-time identification of dispersed electrograms (EGMs) during AFib and atrial tachycardia ablation procedures, analyzing 3D anatomical and electrical maps.
Input Data/Modality	Existing chest and abdominal CT scans	Electrograms (EGMs) and 3D anatomical/electrical maps from EP lab systems

Videos

Demos, reviews, and walkthroughs featuring AI-CVD and VX1.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application of each tool?

AI-CVD is an AI-powered quantitative imaging platform designed for opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. VX1 is an AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.

What type of patient data does each tool utilize?

AI-CVD leverages existing chest and abdominal CT scans to perform its analysis. VX1 integrates with existing electrophysiology (EP) lab mapping and recording systems to analyze 3D anatomical and electrical maps of human atria during ablation procedures.

How do these tools integrate into existing clinical workflows?

AI-CVD is a cloud-based platform that performs opportunistic screening from existing CT scans, designed to cause no additional imaging, radiation, contrast, or workflow disruption. VX1 is deployed as software integrated directly with existing electrophysiology (EP) lab mapping and recording systems.

What specific measurements or insights does each tool provide?

AI-CVD provides automated CT-derived anatomical and density-based measurements, including coronary artery calcium scoring, aortic/mitral valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta/pulmonary artery sizing. VX1 offers AI-guided real-time identification of dispersed electrograms, cycle length estimation from electrograms, and a booster mode for increased sensitivity during AT or slow AF.

Which medical specialties are these tools designed to support?

AI-CVD is designed to support Cardiology, Pulmonology, and Radiology specialties. VX1 is specifically designed to assist cardiac electrophysiologists within the Cardiology specialty.

Does either tool require additional imaging or procedures?

AI-CVD explicitly states that it requires no additional imaging, radiation, contrast, or workflow disruption as it utilizes existing CT scans. VX1 integrates with existing EP lab systems, analyzing data generated during ongoing atrial fibrillation and atrial tachycardia ablation procedures.